Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The authors said their analysis should help clinicians better monitor patients for potential adverse events.

The new data shed light on long-term outcomes for patients receiving duvelisib, although the investigators said the treatment landscape has also shifted significantly since the original trial.

BET inhibition in chronic lymphocytic leukemia (CLL) significantly reduces leukemic cell burden and restores T-cell function by modulating the immune microenvironment and reversing T-cell exhaustion.

A new report finds secondary immunodeficiency disease (SID) also increases the risk of mortality in patients with B-cell malignancies.

A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials.

Due to the rarity of primary breast lymphoma, individualized treatment plans that consider overall health, symptoms, and patient preferences should be curated.

The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of targeted kinase inhibitors.

There was a marked increase in the prevalence of targeted therapy among patients with chronic lymphocytic leukemia (CLL), which corresponded to positive overall survival rates observed in the study.

An overview of the treatments for chronic lymphocytic leukemia (CLL) and novel therapies on the horizon, including double and triple combination therapies, cellular therapies, and bispecific antibodies.

UGT2B17, a metabolic enzyme known for regulating various endogenous molecules, has been identified to have heightened expression in the B cells of patients who have chronic lymphocytic leukemia (CLL).

EVIdeNCE study data, from real-world practice, confirm the efficacy and safety that ibrutinib previously demonstrated in clinical trials involving patients with CLL, according to the study authors.

Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).

Investigators said both reflexology and acupressure led to similar improvement in patients after 4 weeks.

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

Most fragility fractures experienced by people with chronic lymphocytic leukemia (CLL) are vertebral, the study found.

Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.

Studies of DNA methylation, RNA methylation, and histone modification revealed important information about the pathology of chronic lymphocytic leukemia and treatment potential.

Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.

There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.

Advances in multi-omics have led to large scale studies that can provide a better prediction method for adequate therapy choices in patients with chronic lymphocytic leukemia (CLL).

This new analysis provides an optimistic outlook on the future of chronic lymphocytic leukemia (CLL) treatment and discoveries into the background behind CLL transformation into Richter syndrome.

The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery.

A patient with chronic lymphocytic leukemia (CLL) who experience persistent exaggerated responses to insect bites was successfully treated with dupilumab.

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.

Investigators say the findings could lead to new therapeutic targets.

Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.

No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.